SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending after its earnings revealed robust revenue growth but a net loss, primarily due to higher loan loss provisions, which has led to a significant stock decline. While many in the community view it as a broken IPO with a questionable business model, others are aggressively buying the dip, confident in its strong user expansion and strategic market position within the struggling fintech sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following significant news of EU approval for its ANKTIVA bladder cancer therapy and a strategic distribution partnership across Europe, alongside an updated submission to the US FDA for expanded indication. The community is highly engaged, anticipating a major short squeeze and substantial long-term growth while actively discussing market makers attempting to suppress the stock around options expiry.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

The FDA's decision to review Moderna's seasonal flu vaccine application is driving investor optimism and a notable share price surge, while community sentiment remains highly active, weighing this regulatory win against its expanding oncology pipeline and a significant patent infringement trial.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a major competitor, Corcept Therapeutics, received an FDA rejection for its next-gen Cushing's syndrome drug, a development the community views as a significant competitive advantage for XERS's Recorlev. Investors are actively discussing this "irrational" dip as a buying opportunity, anticipating strong Q4 earnings, bullish 2026 guidance, and the advancement of its promising XP-8121 pipeline.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as it reopens deal talks with Paramount Skydance following a sweetened offer including a breakup fee coverage and a ticking fee, escalating the bidding war while shareholders await a vote on Netflix's board-recommended acquisition.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending following a strong earnings report and its expanding role in the agentic AI market, fueling a short squeeze as bulls anticipate further upside, while bears warn of an impending pullback or offering amid notable insider selling.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is trending on investor excitement surrounding its upcoming NYSE Opening Bell ceremony, with community chatter focusing on its low float and high short interest for a potential squeeze. The company's positioning in the commercial aerospace sector, including discussions around hypersonic tech contracts, is driving active debate and bullish sentiment for significant gains.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is experiencing a significant rally following an earnings report that surpassed expectations and included raised guidance, with management signaling a bottoming of the agriculture cycle. However, community sentiment is sharply divided, as many question the sustainability of the surge given concerns about declining revenue, high debt, and valuation, while others celebrate the "homerun" and anticipate further upside.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is seeing high trading volume and significant price volatility after an earnings report that missed revenue and EPS estimates but showcased robust total order and marketplace gross order value growth. This contradictory performance has ignited intense debate among investors, with optimists pointing to strong business expansion and a post-earnings rally, while skeptics emphasize the valuation, cautious Q1 outlook, and analyst price target cuts.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending after its strong earnings beat, increased dividend, and announced 25-for-1 stock split surprisingly resulted in a significant sell-off. Community discussion is heavily focused on whether AI poses a genuine disruptive threat to the travel sector, particularly with Google's expanded AI travel tools, or if market concerns are overstated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LakeShore Biopharma Co., Ltd (LSB) on Thursday announced that its board of directors has received a revised preliminary non-binding proposal letter from a consortium to acquire all of the outstanding ordinary shares of the company in an all-cash transaction for $0.86 per ordinary share.The consortium is comprised of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc. Members of the consortium currently beneficially own in aggregate approximately 52.1% of the company's issued and outstanding ordinary shares.The revised proposal letter, dated August 26, revises the preliminary non-binding proposal letter dated August 18, previously received from Oceanpine Capital.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LSB">LSB stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.LakeShore <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acquire-the-company-and-formation-of-special-committee-302541021.html">said</a> its board has formed a special committee consisting of its three independent directors, Adam Zhao, Thomas Xue, and Chunyang Shao, to evaluate and consider the revised proposal letter and transaction.The company has not made any decisions regarding its response to the proposal, it said, while adding that there is no assurance that a definitive offer will be made or an agreement executed.LakeShore said that the proposed purchase price per share of $0.86, which represents a premium of about 9% from the stock’s closing price on Wednesday, remains unchanged from the original proposal.The members of the consortium, however, have entered into an agreement to vote all of their shares in favor of the proposed transaction. They also do not intend to sell their shares to any third party or support any competing bid while remaining members of the consortium, LakeShore said.LSB stock is down by 77% this year and by 82% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-3-3-in-q2-revised-upwards-from-3/chs6JFbRdmZ">GDP Grows At 3.3% In Q2, Economy Expands At A Faster Clip Than Previously Estimated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LakeShore Biopharma Receives Revised Proposal To Acquire Company

The company said the revised preliminary non-binding letter proposes the acquisition of all outstanding ordinary shares in an all-cash transaction for $0.86 apiece.

Equity

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee LakeShore Biopharma Announces Receipt of a Revised...

LakeShore Biopharma Co. (LSB) on Monday said that its board received a preliminary non-binding proposal letter to acquire all of the outstanding ordinary shares of the company for $0.86 per share.The proposal from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. was dated August 18 and is for all shares not currently owned by Oceanpine Capital, the company said. The price of $0.86 represents a premium of 10.3% to the stock’s closing price on August 15.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html">said</a> that the board will carefully review and evaluate the proposal to determine the future course of action. However, the board has not made any decisions on the proposal, and there is no assurance that any agreement will be executed, it added.On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/LSB">LakeShore</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.The proposed transaction will be funded with rollover equity and available cash on hand and will not be subject to a financing condition, Oceanpine said in its letter. “While we are fully prepared to work collaboratively with the Board to pursue the proposed transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company's shareholders,” Oceanpine said in its letter.LakeShore Biopharma operates in China, Singapore, and the Philippines. Its main product is a freeze-dried human rabies vaccine.LSB stock is down by 77% this year and by about 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharma-stock-rises-pre-market-after-fda-approval-for-drug/chsO9FfRdXb">This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside 

The offer price of $0.86 represents a premium of 10.3% to the company's last closing price on August 15.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

LSB
LakeShore Biopharma Co Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest LSB News

LSBLakeShore Biopharma Co Ltd.